- Home
- CENN vs AEON Comparison
CENN vs AEON Comparison
Compare CENN & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CENN
- AEON
- Stock Information
- Founded
- CENN 2013
- AEON N/A
- Country
- CENN United States
- AEON United States
- Employees
- CENN N/A
- AEON N/A
- Industry
- CENN Auto Manufacturing
- AEON Biotechnology: Pharmaceutical Preparations
- Sector
- CENN Consumer Discretionary
- AEON Health Care
- Exchange
- CENN Nasdaq
- AEON Nasdaq
- Market Cap
- CENN 35.8M
- AEON 36.4M
- IPO Year
- CENN N/A
- AEON N/A
- Fundamental
- Price
- CENN $1.36
- AEON $0.61
- Analyst Decision
- CENN
- AEON Strong Buy
- Analyst Count
- CENN 0
- AEON 1
- Target Price
- CENN N/A
- AEON $5.00
- AVG Volume (30 Days)
- CENN 102.0K
- AEON 90.7K
- Earning Date
- CENN 11-12-2024
- AEON 11-13-2024
- Dividend Yield
- CENN N/A
- AEON N/A
- EPS Growth
- CENN N/A
- AEON N/A
- EPS
- CENN N/A
- AEON N/A
- Revenue
- CENN $37,052,841.00
- AEON N/A
- Revenue This Year
- CENN N/A
- AEON N/A
- Revenue Next Year
- CENN N/A
- AEON N/A
- P/E Ratio
- CENN N/A
- AEON N/A
- Revenue Growth
- CENN 142.48
- AEON N/A
- 52 Week Low
- CENN $1.00
- AEON $0.60
- 52 Week High
- CENN $25.00
- AEON $17.17
- Technical
- Relative Strength Index (RSI)
- CENN 58.62
- AEON 28.19
- Support Level
- CENN $1.30
- AEON $0.65
- Resistance Level
- CENN $1.30
- AEON $0.88
- Average True Range (ATR)
- CENN 0.07
- AEON 0.07
- MACD
- CENN 0.01
- AEON -0.03
- Stochastic Oscillator
- CENN 50.00
- AEON 1.75
About CENN Cenntro Electric Group Limited
Cenntro Inc is a designer, manufacturer, distributor, and service provider of commercial vehicles. Its vehicles include Metro, Logistar 400, Logistar 200, Neibor 200, and ORV. The company's geographical segments include Europe, America, and Asia.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.